Avicanna Inc. (AVCN) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

All right. We'll get started. Thank you for joining everyone. My name is Arat Azadian, CEO and Founder of Avicanna. Some of you would know me for a long time. This is my tenth year in the role. Joined today by with Doctor. Caroline Irvin, who is our EVP of Scientific Affairs and Medical Affairs and Nick Auburn, who is our Interim CFO. We're going to take you over some of the corporate updates from 2025, then a little bit of an overview of where we stand as a corporation. But of course, I look forward as well into 2026 and what's coming, which is very exciting. In addition to that, we're going to leave a little bit of time for Q and A at the end. So customary disclaimer notice, But for some of you that are new to the company, I'll spend a minute or two on just who we are. So Avicanna is now a fully vertically integrated cannabinoid based pharma company. We have established what we believe is an industry leading scientific platform and that is now translated into a commercial platform. This is across four different business pillars now from medical cannabis products, mainly the Rophyto brand to our medical cannabis care platform, which is mymedi.ca, to our pharmaceutical pipeline and of course, our Arias raw material division. This is all part of an integrated commercial platform. These business units, while we do operate independently, do have substantial synergistic benefits for each other business unit. This has resulted in over 50 commercial products, mainly in the Canadian market. This is part of our plans for 2026 to further expand these into international markets. And we have established footprint and or proof of concept in what is now '24 international markets resulting in about $25,500,000 of revenue during 2025 and essentially a bit, I guess, at a bit of brea...